Skip to content
Sign up today for access to the latest pediatric solutions!
Sign up today for access to the latest pediatric solutions!

IP License - FOXP3+ Helios+ Engineered Regulatory T cells

IP Licensing
Availability: Available On Demand

For informational purposes only. Please contact seller directly for more details.

Share This:

Children’s Mercy Kansas City, together with the University of Kansas, has developed a novel cell-based therapy to combat disordered inflammation. Using a novel method, CD4+ and CD8+ regulatory T cells have been engineered to over express both FOXP3 and Helios without suppression of either product. Efficacy of the eTregs has been shown in vitro and in a humanized model of graft versus host disease (GVHD). CD4+ and CD8+ cells can be separated if preferred. This innovation is applicable in the treatment of diseases in which it is desirable to reduce inflammatory immune response such as type 1 diabetes, multiple sclerosis, allograft/transplant rejection, inflammatory bowel disease, lupus, rheumatoid arthritis, and other chronic inflammatory diseases. If interested in licensing and/or research collaborations, contact Children’s Mercy Kansas City to have discussions. US Patent Issued, Second US and International patents pending.

Shipping Information

Free shipping on orders in the continental United States.
We are unable to ship outside of the United States at this time.

Returns

Please contact the seller directly for their return policy and to handle returns. Customer will be responsible for return shipping fees.